~~<i id='547C0CAC1C'><strike id='547C0CAC1C'><tt id='547C0CAC1C'><pre id='547C0CAC1C'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：knowledge 2025-10-01 11:11:25 Page View：11

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： David Sabatini, ex
Next article： Peter Hotez and the public health issue of online harassment

explore

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

SCOTUS to consider access to abortion pill mifepristone

AprotesterstandsoutsidetheSupremeCourtinWashingtoninApril2023.ShuranHuang/TheNewYorkTimesWASHINGTON—

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Scientists successfully use ultrasound imaging to map brain activity

AdobeResearchersmayhaveanewwaytowatchthebrainpulse,thankstoanultrasoundprobeandatinywindowintheskull